carmustine has been researched along with Carcinoma 256, Walker in 8 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Carcinoma 256, Walker: A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "LDE-carmustine was able to decrease tumour mass at a lower dose level than free carmustine." | 1.32 | Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE). ( Curi, R; Maranhão, RC; Teixeira, RS, 2004) |
| "Fotemustine was cleared 2-5 times more slowly than BCNU from tumor tissue, and its clearance was higher in W256/B- than in W256/A-bearing rats." | 1.28 | Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma. ( Bartosek, I; Corada, M; Garattini, S; Guaitani, A; Lemoine, A; Lucas, C, 1991) |
| " In dose-response studies low doses of the new analogs effected a higher tumor weight inhibition than BCNU in the treatment of subcutaneously implanted Walker 256." | 1.26 | Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat. ( Eisenbrand, G; Fiebig, HH; Zeller, WJ; Zentgraf, R, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teixeira, RS | 1 |
| Curi, R | 1 |
| Maranhão, RC | 1 |
| Horgan, CM | 1 |
| Tisdale, MJ | 1 |
| Fiebig, HH | 3 |
| Eisenbrand, G | 3 |
| Zeller, WJ | 3 |
| Zentgraf, R | 1 |
| Bartosek, I | 2 |
| Russo, RG | 1 |
| Cattaneo, MT | 1 |
| Deutsch-Wenzel, T | 1 |
| Guaitani, A | 1 |
| Corada, M | 1 |
| Lucas, C | 1 |
| Lemoine, A | 1 |
| Garattini, S | 1 |
| Ford, JM | 1 |
| Hait, WN | 1 |
| Matlin, SA | 1 |
| Benz, CC | 1 |
8 other studies available for carmustine and Carcinoma 256, Walker
| Article | Year |
|---|---|
Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE).
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma 256, Walker; Carmustine; Cholesterol Esters; E | 2004 |
Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carmus | 1984 |
Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Bone Marrow; Carcinoma 256, Walker | 1980 |
Pharmacokinetics of nitrosoureas: levels of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in organs of normal and Walker 256/B carcinoma bearing rats after i.v. bolus.
Topics: Adipose Tissue; Animals; Carcinoma 256, Walker; Carmustine; Injections, Intravenous; Kinetics; Liver | 1984 |
Some new congeners of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Synthesis of bifunctional analogs and water soluble derivatives and preliminary evaluation of their chemotherapeutic potential.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carmustine; Chemical Phenomena; Chemistry; Le | 1976 |
Water soluble derivatives and bifunctional analogs of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Topics: Animals; Carcinoma 256, Walker; Carmustine; Male; Mammary Neoplasms, Experimental; Neoplasms, Experi | 1977 |
Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carmustine; Cell Line; Dose-Response Relation | 1991 |
Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
Topics: Alkylating Agents; Animals; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma 256, Walker; Carmust | 1991 |